earnings
confidence high
sentiment positive
materiality 0.60
IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end
Insight Molecular Diagnostics Inc.
2025-Q2 EPS
reported -$0.57
vs consensus -$0.23
▼ miss
(-143.0%)
- Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.
- Net loss $9.7M ($0.30/sh); non-GAAP operating loss $5.98M.
- Cash $26.0M; quarterly cash spend ~$6M, in line with target.
- FDA submission for GraftAssureDx on track for end-2025; marketing authorization expected mid-2026.
- First RUO kit sale to Swiss hospital; Medicare boost to $2,753/test.